# US 2026/0035340 A1 · Inhibitors of akr1c3 and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0035340 A1
- Document ID: US20260035340A1
- Status: Published application
- Kind: A1
- Application number: 19/099,792
- Filed: 2023-08-04
- Published: 2026-02-05
- Earliest claimed: 2022-08-05
- Assignees: Board of Regents of the University of Nebraska; The Trustees of the University of Pennsylvania
- Applicants: Board of Regents of the University of Nebraska; The Trustees of the University of Pennsylvania
- Inventors: Paul Trippier; Krishnaiah Maddeboina; Sravan Jonnalagadda; Trevor Penning
- Web page: https://patentgrep.com/patent/US20260035340A1

## CPC

- C07C 233/65: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07C 233/42: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C 235/42: having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C 235/46: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 255/41: the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 215/14: Radicals substituted by oxygen atoms
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 295/073: with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 317/48: Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D 317/60: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 319/18: Ethylenedioxybenzenes, not substituted on the hetero ring
- C07D 471/04: Ortho-condensed systems
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds having a structure of formula (A), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rd and n are described herein. Also provided herein are compositions comprising compounds of Formula (A) and methods of using compound of Formula (A) in treating, inhibiting, and/or preventing disease such as cancers (e.g., prostate cancer).

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, having a structure of formula (A):
wherein
R1 is selected from substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C2-C6alkynyl, substituted or unsubstituted C1-C6alkyl, C2-C6alkenyl, substituted or unsubstituted C3-C6alkenyloxy, halo, substituted or unsubstituted C6-C10aryl-C1-C3alkyleneoxy, C6-C10aryloxy, and substituted or unsubstituted C5-C10heteroaryl having 1-4 ring heteroatoms selected from N, O, and S;
wherein R1 is optionally substituted with one or more substituents selected from C6-C10aryl; 5-15 membered heteroaryl having 1-4 ring heteroatoms selected from N, O, and S; formyl, C3-C6cycloalkyl, halo, cycloheteroalkyl-alkylene, hydroxy-C1-C3alkylene, methoxymethyl, phenyoxy, cyano, C1-C6alkyl, C1-C6haloalkyl, and 5-7 membered fused cycloheteroalkyl having 1 to 3 ring heteroatoms selected from N, O, and S;
R2 is selected from CO2Ra, CONRbRc, wherein each Ra, Rb, and Rc is independently H or C1-C6alkyl;
each R3 and R4 is independently H or C1-C6alkyl;
each Rd is independently H or C1-C3alkyl; and
n is 1, 2, or 3.

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R1 is selected from:

### Claim 3 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R1 is selected from:

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R1 is selected from:

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R2 is selected from —CO2H, —CO2CH3, —CO2CH2CH3, —CO2(CH2)2CH3, —CO2C(CH3)3, —CONH2, —CON(CH3)2, and —CN.

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R2 is CO2H.

### Claim 7 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R3 is H.

### Claim 8 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein R4 is C1-C6alkyl.

### Claim 9 (depends on 8)

The compound or pharmaceutically acceptable salt of claim 8, wherein R4 is methyl.

### Claim 10 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein one or more Rd is ethyl.

### Claim 11 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein formula (A) is selected from:

### Claim 12 (depends on 11)

The compound or pharmaceutically acceptable salt of claim 11, wherein R2 of formula A-4 is selected from —CN, —CONH2, —CON(CH3)2, and —CO2CH3.

### Claim 13 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1, wherein the structure of formula (A) is selected from the group consisting of

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the compound of formula (A) or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the compound of formula (A) is selected from a compound of

### Claim 16 (depends on 14)

The pharmaceutical composition of claim 14 comprising a compound or pharmaceutically acceptable salt thereof selected from the group consisting of

### Claim 17 (depends on 1)

A method of inhibiting AKR1C3 comprising contacting AKR1C3 with a compound or pharmaceutically acceptable salt of formula (A) according to claim 1 in an amount effective to inhibit AKR1C3.

### Claim 18 (depends on 1)

A method of treating and/or preventing a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (A) or pharmaceutically acceptable salt according to claim 1.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The method of claim 18, wherein the disease is a cancer is selected from leukemia (e.g., acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, T-cell acute lymphoblastic leukemia), lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma), multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, colon cancer, thyroid cancer, bladder cancer, liver cancer, neuroblastoma, brain cancers (e.g., gliomas, meningiomas, pituitary adenomas, etc.), lung cancer, ovarian cancer, stomach cancer, skin cancer (melanoma), cervical cancer, testicular cancer, kidney cancer, carcinoid tumors, bone cancer, and endometrial cancer.

### Claim at position 21

-30. (canceled)

### Claim 31 (depends on 1)

A method of enhancing or potentiating the effectiveness of an active agent comprising administering the active agent in combination with an effective amount of a compound or pharmaceutically acceptable salt according to claim 1.

### Claim at position 23

-42. (canceled)
